Tech startups such as Sona, Rocketlane, Vitestro, among others, have announced their venture capital funding to bolster innovation and business growth.
Sona Raises $45M Series B to Power Frontline Business AI
Sona raised $45 million in a Series B funding led by N47 with participation from Felicis, Northzone, Gradient, and Italian Founders Fund, bringing total funding above $100 million. The investment will accelerate expansion of its AI operational platform for the frontline economy — powering scheduling, HR, payroll, and other mission critical workflows. Sona’s real time platform infrastructure enables distributed businesses to replace fragmented legacy systems with a coordinated, intelligent foundation. The capital supports U.S. expansion and rapid delivery of planned capabilities, emphasizing AI as integral infrastructure in operational tech stacks across sectors like hospitality, retail, healthcare, and logistics.
Rocketlane Raises $60M Series C for AI Powered Professional Services
Rocketlane announced a $60 million Series C led by Insight Partners, bringing total invested capital to $105 million. The investment will accelerate growth of its AI powered Professional Services Automation (PSA) platform, designed to help enterprise services teams deliver outcomes at scale. Rocketlane’s Nitro agentic execution platform automates delivery workflows, enabling teams to translate AI pilots into measurable results. Funds will support global expansion, product innovation, and scaling of engineering and customer success capabilities. This positions Rocketlane at the heart of enterprise adoption trends where AI accelerates execution, consistency, and business ROI.
Vitestro Secures $70M Series B to Advance Autonomous Medical Robotics
Vitestro closed a $70 million Series B oversubscribed financing with strategic participation from healthcare VCs, including Labcorp Venture Fund, Mayo Clinic, and Sutter Health alongside Invest NL and others. The funding will accelerate development of its autonomous robotic phlebotomy platform — a next generation automated blood draw device designed for high volume clinical use. Capital will support clinical studies, regulatory pathways, manufacturing scale up, and commercial readiness. This funding underscores investor confidence in AI enabled robotics applied to core healthcare workflows and deep integration into clinical infrastructure and commercial ecosystems.
THASNIYA VP
